《Lung Cancer》重点专注发布医学-呼吸系统领域的新研究，旨在促进和传播该领域相关的新技术和新知识。鼓励该领域研究者详细地发表他们的高质量实验研究和理论结果。根据网友分享的投稿经验，平均审稿速度为 一般,3-6周 约5.9周。该杂志创刊至今，在医学-呼吸系统领域，影响力非凡，对来稿文章质量要求很高，稿件投稿过审难度很大，刊登文章的学术水平和编辑质量在同类杂志中均名列前茅。如果你想在该杂志上发表论文，你可以向编辑部提交文章，但文章必须具有重要意义并代表该领域专业的发展。我们欢迎广大同领域的研究者提交投稿。
| CiteScore | SJR | SNIP | CiteScore排名 | |||
|---|---|---|---|---|---|---|
| 9.4 | 1.761 | 1.18 | 学科类别 | 分区 | 排名 | 百分位 |
|
大类：大类：Medicine
小类：小类：PulmonaryandRespiratoryMedicine
|
Q1 | 20/155 | 87% | |||
|
大类：大类：Medicine
小类：小类：Oncology
|
Q1 | 67/404 | 83% | |||
|
大类：大类：Medicine
小类：小类：CancerResearch
|
Q1 | 58/230 | 75% | |||
| 按JIF指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：ONCOLOGY | SCIE | Q1 | 78 / 322 | 75.9% |
| 学科：RESPIRATORY SYSTEM | SCIE | Q1 | 20 / 100 | 80.5% |
| 按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：ONCOLOGY | SCIE | Q1 | 67 / 322 | 79.35% |
| 学科：RESPIRATORY SYSTEM | SCIE | Q1 | 21 / 101 | 79.7% |
文章名称
引用次数
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
74
Radiomics and radiogenomics in lung cancer: A review for the clinician
68
KRAS-Mutant non-small cell lung cancer: From biology to therapy
46
Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer
32
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
32
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
31
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
31
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions
28
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE- KEYNOTE- and KEYNOTE-042 studies
27
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
26
国家/地区
发文量
TEngland
626
TUSA
260
TCHINA MAINLAND
211
TJapan
167
TItaly
94
TFrance
77
TGERMANY (FED REP GER)
74
TNetherlands
72
TScotland
70
TSouth Korea
69
